Drug Discoveries & Therapeutics
Online ISSN : 1881-784X
Print ISSN : 1881-7831
ISSN-L : 1881-7831
Letter
Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine
Jianjun SunHongzhou Lu
Author information
JOURNAL FREE ACCESS

2021 Volume 15 Issue 4 Pages 225-226

Details
Abstract

Combined antiretroviral therapy (cART) has significantly reduced human immunodeficiency virus (HIV) associated morbidity and mortality and turned HIV infection into a manageable chronic condition. However, lifelong cART is still required. Two-drug regimens could reduce the number of HIV agents and lower the adverse events caused by lifelong medication. A new two-drug regimen, DEVATO, consisting of dolutegravir and lamivudine has durable efficacy, is well-tolerated, and has a high barrier to viral resistance, which is why it is recommended as a new first-line treatment option for people living with HIV infection.

Information related to the author
© 2021 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article
feedback
Top